» Articles » PMID: 20479778

Imaging Renal Cell Carcinoma with Ultrasonography, CT and MRI

Overview
Journal Nat Rev Urol
Specialty Urology
Date 2010 May 19
PMID 20479778
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The increased use of abdominal imaging techniques for a variety of indications has contributed to more-frequent detection of renal cell carcinoma (RCC). Ultrasonography has been used to characterize the solid versus cystic nature of renal masses. This modality has limitations, however, in further characterization of solid tumors and in staging of malignancy, although contrast-enhanced ultrasonography has shown promise. Cross-sectional imaging with multiplanar reconstruction capability via CT or MRI has become the standard-bearer in the diagnosis, staging and surveillance of renal cancers. The use of specific protocols and the exploitation of different imaging characteristics of RCC subtypes, including variations in contrast agent timing, MRI weighting and digital subtraction, have contributed to this diagnostic capability. Cystic renal masses are a special case, evaluation of which can require multiple imaging modalities. Rigorous evaluation of these lesions can provide information that is crucial to prediction of the likelihood of malignancy. Such imaging is not without risk, however, as radiation from frequent CT imaging has been implicated in the development of secondary malignancies, and contrast agents for CT and MRI can pose risks, particularly in patients with compromised renal function.

Citing Articles

A contrast-enhanced computed tomography-based radiomics nomogram for preoperative differentiation between benign and malignant cystic renal lesions.

Yu T, Yan Z, Li Z, Yang M, Yu Z, Chen Y Transl Androl Urol. 2024; 13(6):949-961.

PMID: 38983472 PMC: 11228685. DOI: 10.21037/tau-23-656.


Clinical T1/2 renal cell carcinoma: multiparametric dynamic contrast-enhanced MRI features-based model for the prediction of individual adverse pathology.

Wang K, Guo B, Yao Z, Li G World J Surg Oncol. 2024; 22(1):145.

PMID: 38822338 PMC: 11143715. DOI: 10.1186/s12957-024-03431-4.


Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.

Sadaghiani M, Baskaran S, Gorin M, Rowe S, Provost J, Teslenko I J Nucl Med. 2024; 65(7):1007-1012.

PMID: 38782453 PMC: 11218724. DOI: 10.2967/jnumed.124.267417.


A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma.

Wen Z, Li Y, Zhao Z, Li R, Li X, Lu C Cancer Cell Int. 2024; 24(1):18.

PMID: 38191389 PMC: 10773017. DOI: 10.1186/s12935-023-03187-z.


CD56 polysialylation promotes the tumorigenesis and progression via the Hedgehog and Wnt/β-catenin signaling pathways in clear cell renal cell carcinoma.

Jian Y, Zhang L, Gong L, Ding M, Sun X, Yu X Cancer Cell Int. 2023; 23(1):319.

PMID: 38087309 PMC: 10717404. DOI: 10.1186/s12935-023-03165-5.


References
1.
Studer U, Scherz S, Scheidegger J, Kraft R, SONNTAG R, Ackermann D . Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol. 1990; 144(2 Pt 1):243-5. DOI: 10.1016/s0022-5347(17)39422-3. View

2.
Piscaglia F, Bolondi L . The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006; 32(9):1369-75. DOI: 10.1016/j.ultrasmedbio.2006.05.031. View

3.
Sandrasegaran K, Sundaram C, Ramaswamy R, Akisik F, Rydberg M, Lin C . Usefulness of diffusion-weighted imaging in the evaluation of renal masses. AJR Am J Roentgenol. 2010; 194(2):438-45. DOI: 10.2214/AJR.09.3024. View

4.
Pedrosa I, Chou M, Ngo L, Baroni R, Genega E, Galaburda L . MR classification of renal masses with pathologic correlation. Eur Radiol. 2007; 18(2):365-75. DOI: 10.1007/s00330-007-0757-0. View

5.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View